Tagged: biotech

$17.5 million equity placement completed by Intralytix


XDATA – June 12th 2017
Intralytix disclosed raising $17.5 million as part of a non-brokered equity private placement. One investor acquired the securities almost two weeks ago. The equity offering’s estimated net proceeds amount to $15.62 million excluding $1.88 million earmarked for the payment of officers’ salaries. No offering was previously initiated by the company under a registration exemption with the SEC.
The company is a biotechnology specialized in bacteriophage-based products used to control bacterial pathogens in environmental, food processing, and medical settings.
The company is headquartered in Baltimore MD. Intralytix elected to keep its revenues undisclosed.
The executive team includes Alexander Sulakvelidze, John J Woloszyn and Mel Ruzicka.
The board of directors includes Gary Pasterneck and Patrick Hervy.
Offering recap
Status: Completed
Company: Intralytix
Industry: Other
Amount offered: $17.5 million
Amount placed: $17.5 million
SEC filing: Source
First sale: 05-31-2017
Data as of: 06-12-2017
Advertisements

$47.7 million raised so far by Atterocor via private placement


XDATA – January 4th 2016
Atterocor disclosed selling 67% of its $70.7 million brokered equity offering to twenty-one investors. The sale started on December 18th according to the document filed at the SEC. $23.01 million in additional funding can be raised before December 2016 based on the placement’s structure. The private placement’s expected net proceeds will amount to $70.2 million excluding $500,000 paid in brokerage fees by the company. Two previous unregistered financing rounds raised an estimated $17.13 million.
The company is focused on the accelerated development of a novel treatment for adrenal cancer, a rare endocrine cancer. Investors include Osage Partners, Frazier Healthcare and 5AM Ventures, The Regents of the University of Michigan through its “MINTS” program, and The Michigan Pre-Seed Capital Fund.
The company, headquartered in Ann Arbor MI, is led by Julia C Owens (President and CEO). Atterocor elected to keep its revenues undisclosed.
The board of directors includes Carol Gallagher, James Topper, Randall Whitcomb and William Harrington.

The company has raised an estimated total of $64.83 million via private unregistered security offerings.

Offering recap
Status: First close
Company: Atterocor
Industry: Pharmaceuticals
Amount offered: $70.7 million
Amount placed: $47.7 million
SEC filing: Source
First sale: 12-18-2015
Data as of: 01-04-2016

$543.17 million equity placement completed by Akcea Therapeutics


XDATA – January 4th 2016
Akcea Therapeutics disclosed raising $543.17 million as part of a non-brokered equity private placement. One investor acquired the securities on December 18th. No offering was previously initiated by the company under a registration exemption with the SEC.
The issuance includes cash and non-cash consideration, including the grant of certain rights and licenses.
The company is focused on the development and commercialization of Ionis Pharmaceuticals’ lipid portfolio of novel new medicines for the treatment of serious cardiometabolic lipid disorders. Established as. Investors include Ionis Pharmaceuticals.
The company was registered in 2015 and has its headquarters located in Cambridge MA. Akcea Therapeutics elected to keep its revenues undisclosed.
The executive team includes Elizabeth L Hougen, Jeffrey Goldberg, Patrick O’Neil, Paula Soteropoulos and Stanley T Crooke.
The board of directors includes B Lynne Parshall.
Offering recap
Status: Completed
Company: Akcea Therapeutics
Industry: Pharmaceuticals
Amount offered: $543.17 million
Amount placed: $543.17 million
SEC filing: Source
First sale: 12-18-2015
Data as of: 01-04-2016

Arvinas Holding Company completed a new $41.61 million equity offering


XDATA – October 23rd 2015
Arvinas Holding Company issued equity for a total of $41.61 million in a non-brokered investment round. The transaction which started a week ago, garnered the support of sixteen investors. No offering was previously initiated by the company under a registration exemption with the SEC.
Arvinas Holding Company develops novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Central to the company’s proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body. The company is backed by Merck.
The company was registered in 2014 and has its headquarters located in New Haven CT. Arvinas Holding Company elected to keep its revenues undisclosed.
The executive team includes Manuel Litchman and Sean Cassidy.
The board of directors includes Andrew Levin, Brad Margus, Jonathan Soderstrom, Kush Parmar, Liam Ratcliffe, Stephen Squinto and Tim Shannon.
Offering recap
Status: Completed
Company: Arvinas Holding Company
Industry: Biotechnology
Amount offered: $41.61 million
Amount placed: $41.61 million
SEC filing: Source
First sale: 10-16-2015
Data as of: 10-23-2015

 

Hey if you didn’t know about it, maybe it is time to add XDATA as part of your market monitoring regimen.

For more information visit www.XDATA.co

$21.86 million raised so far by Rheonix via private placement


XDATA – October 9th 2015
Rheonix disclosed selling 60% of its $36.5 million non-brokered equity offering to twenty-four investors. The sale started a little over a week ago according to the document filed at the SEC. $14.64 million in additional funding can be raised before September 2016 based on the placement’s structure. The company closed four previous unregistered private placements which raised an estimated $30.52 million.
Rheonix commercializes the Encompass Optimum platform, a highly customizable technology offering versatility and affordability for use in research laboratories. The platform performs fully automated, complex molecular assays in an easy-to-use and economical format on the company’s CARD cartridge. The company is backed by Cayuga Venture Fund, Gefinor Ventures and Rand Capital.
The company is headquartered in Ithaca NY. Rheonix elected to keep its revenues undisclosed.
The executive team includes Anthony Eisenhut, Christopher Smith, Gregory Galvin and John Brenner.

The company has raised an estimated total of $52.39 million via private unregistered security offerings.

Offering recap
Status: First close
Company: Rheonix
Industry: Other Technology
Amount offered: $36.5 million
Amount placed: $21.86 million
SEC filing: Source
First sale: 09-29-2015
Data as of: 10-09-2015

Hey if you didn’t know about it, maybe it is time to add XDATA as part of your market monitoring regimen, 14 days free trials are available here.

For more information visit www.XDATA.co

$71 million pre-IPO financing round completed by Conkwest


conkwestHey if you didn’t know about it, maybe it is time to add XDATA as part of your market monitoring regimen, 14 days free trials are available here.

A $71 million unregistered equity financing by Conkwest successfully drew to a close. The non-brokered investment round was placed among nine investors. The subscription started almost two weeks ago. A total of five unregistered securities offerings closed by the company raised an estimated $69.17 million.
Conkwest develops and commercializes a product pipeline for the treatment of cancers and viral infections. The company’s products are based on the proprietary cancer-killing cell line Neukoplast (also known as NK-92) – the only cell line that can be commercialized as a direct, scalable, off-the-shelf cancer-killing product. The company is backed by Dr. Patrick Soon-Shiong and Sorrento Therapeutics.
The company is headquartered in Cardiff-by-the-sea CA. Conkwest elected to keep its revenues undisclosed.
The executive team includes Barry J Simon, Patrick Soon-Shiong and Richard Gomberg.
The board of directors includes Hans Klingemann, Henry Ji, John C Thomas, John T Potts, Richard Kusserow, Robert Rosen and Steve Gorlin.The company has raised an estimated total of $140.17 million via private unregistered security offerings.
Offering recap
Status: Completed
Company: Conkwest
Industry: Biotechnology
Amount offered: $71 million
Amount placed: $71 million
SEC filing: Source
First sale: 06-10-2015
Data as of: 06-22-2015

For more information visit www.XDATA.co

Mousera reported the completion of a $20 million financing round


mouseraMaybe it is time to add XDATA as part of your market monitoring regimen, 14 days free trials are available here.

$20 million was raised by Mousera following the successful placement and issuance of its unregistered equity securities. A total of twenty-two investors participated to the non-brokered placement which started on May 26th. Two previous unregistered financing rounds raised an estimated $9.99 million.
Mousera develops big data tools and algorithms to speed-up pre-clinical research and development of drugs for the pharmaceutical industry.
Timothy L Robertson (CEO) leads the San Mateo CA based company which was registered in 2013. Mousera elected to keep its revenues undisclosed.
The executive team includes Jonathan Betts-Lacroix and Timothy Robertson.
The board of directors includes Jeff Kindler and Matt Ocko.

The company has raised an estimated total of $29.99 million via private unregistered security offerings.

Offering recap
Status: Completed
Company: Mousera
Industry: Other
Amount offered: $20 million
Amount placed: $20 million
SEC filing: Source
First sale: 05-26-2015
Data as of: 06-09-2015

For more information visit www.XDATA.co

Vivo and InterWest backed Eiger Bio closed on additional financing


eigerHey if you didn’t know about it, maybe it is time to add XDATA as part of your market monitoring regimen, 14 days free trials are available here. You can find the story and many more on qbeats as well.

For more information visit www.XDATA.co

Balance Therapeutics closes $15mn+ financing round


Balance therapeuticsThe company is backed by Mohr Davidow Ventures, Pappas Ventures, and Stanford University. Hey, if you didn’t know about it, maybe it is time to add XDATA as part of your market monitoring regimen, 14 days free trials are available here. You can find the story and many more on qbeats as well.

For more information visit www.XDATA.co

Seres Health reported the completion of a $48 million financing round


seresHealth$48 million was raised by Seres Health following the successful placement and issuance of its unregistered equity securities. A total of twenty investors participated to the non-brokered placement which started a little over a week ago. Until this disclosure Seres Health had raised an estimated $10.63 million in unregistered securities via one previous financing round.

Seres Health develops Ecobiotic therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. The company is backed by VentureLabs, Flagship Ventures’ innovation foundry.

The company, headquartered in Cambridge MA, is led by Roger J Pomerantz (President and CEO). Seres Health elected to keep its revenues undisclosed.
The executive team includes David Cook, Eric D Shaff and John Aunins.
The board of directors includes David Berry, Lorence Kim, Noubar Afeyan, Peter Barton Hutt, Richard Kender and Werner Cautreels.

The company has raised an estimated total of $58.63 million via private unregistered security offerings.

Offering recap
Status: Completed
Company: Seres Health
Industry: Pharmaceuticals
Amount offered: $48 million
Amount placed: $48 million
SEC filing: Source
First sale: 11-24-2014
Data as of: 12-02-2014


For more information visit www.XDATA.co